Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

被引：2
|
作者：
Pettus, Jeremy
Vajda, Eric G.
Pipkin, James
Williamson, Gretchen
Zangmeister, Miriam A.
Li, Yong-Xi
Henry, Robert R.
D'Alessio, David
Frias, Juan P.
Zhi, Lin
Marschke, Keith
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-73-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Saxagliptin Improves Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment Compared with Placebo
    Owens, David R.
    Swallow, Ros
    Jones, Peter
    Dugi, Klaus A.
    Woerle, Hans-Juergen
    DIABETES, 2010, 59 : A149 - A150
  • [42] Rosiglitazone monotherapy significantly lowers HbA1c levels in treatment-naive type 2 diabetic patients
    Grunberger, G
    Dole, JF
    Freed, MI
    DIABETES, 2000, 49 : A109 - A109
  • [43] Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
    Pettus, Jeremy
    Boeder, Schafer C.
    Christiansen, Mark P.
    Denham, Douglas S.
    Bailey, Timothy S.
    Akturk, Halis K.
    Klaff, Leslie J.
    Rosenstock, Julio
    Cheng, Mickie H. M.
    Bode, Bruce W.
    Bautista, Edgar D.
    Xu, Ren
    Yan, Hai
    Thai Dung
    Garg, Satish K.
    Klein, Samuel
    NATURE MEDICINE, 2022, 28 (10) : 2092 - +
  • [44] Slope of Decline in HbA1c with Empagliflozin Appears to Be Greater than the Slope with Sitagliptin or Glimepiride in Patients with Type 2 Diabetes (T2DM)
    Defronzo, Ralph A.
    Elsasser, Ulrich
    Lund, Soren S.
    Hach, Thomas
    DIABETES, 2015, 64 : A331 - A332
  • [45] Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
    Jeremy Pettus
    Schafer C. Boeder
    Mark P. Christiansen
    Douglas S. Denham
    Timothy S. Bailey
    Halis K. Akturk
    Leslie J. Klaff
    Julio Rosenstock
    Mickie H. M. Cheng
    Bruce W. Bode
    Edgar D. Bautista
    Ren Xu
    Hai Yan
    Dung Thai
    Satish K. Garg
    Samuel Klein
    Nature Medicine, 2022, 28 : 2092 - 2099
  • [46] Single Doses of the Glucagon Receptor Antagonist LY2409021 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2DM)
    Kelly, Ronan P.
    Abu-Raddad, Eyas J.
    Tham, Lai San
    Fu, Haoda
    Pinaire, Jane A.
    Deeg, Mark A.
    DIABETES, 2011, 60 : A275 - A275
  • [47] Changes in HbA1c Level over a 12-Week Follow-up in Patients with Type 2 Diabetes following a Medication Change
    Hirst, Jennifer A.
    Stevens, Richard J.
    Farmer, Andrew J.
    PLOS ONE, 2014, 9 (03):
  • [48] Most Hypogonadal Men with Type 2 Diabetes Mellitus (T2DM) Achieve HbA1c Targets when Treated with Testosterone Undecanoate (TU) Injections for Up to 12 Years
    Saad, Farid
    Doros, Gheorghe
    Yassin, Aksam
    DIABETES, 2017, 66 : A305 - A305
  • [49] Effect of Glycated Haemoglobin (HBA1c) on Cardiorespiratory Fitness (CRF) in a Population with Type 2 Diabetes Mellitus (T2DM): A Cross-Sectional Study
    Dixit, Snehil
    Bassi-Dibai, Daniela
    Dibai-Filho, Almir Vieira
    Mendes, Renata G.
    Alqahtani, Abdulfattah S.
    Alshehri, Mohammed M.
    Aldhahi, Monira I.
    Alkhamis, Batool Abdulelah
    Reddy, Ravi Shankar
    Tedla, Jaya Shanker
    Borghi-Silva, Audrey
    MEDICINA-LITHUANIA, 2024, 60 (11):
  • [50] Correlation of HbA1c with daily fluctuation of blood glucose in insulin treated patients with Type 2 diabetes mellitus (T2 DM).
    Kalyvinos, A
    Bakatselos, S
    Tsapas, B
    Papadopoulos, G
    Sakallerou, A
    Pitsava, E
    Hatzileftheriou, H
    DIABETOLOGIA, 2003, 46 : A240 - A240
12345